Top Page
Aptamer Group Plc
(LSE:APTA)
Aptamer Group Plc (APTA) vs. iShares MSCI United Kingdom ETF (EWC)
Aptamer Group Plc Business Overview & Revenue Model
Aptamer Group Plc Financial Statement Overview
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 1.20M | 1.20M | 860.00K | 1.75M | 4.04M | 1.28M |
| Gross Profit | 465.00K | 350.00K | 250.00K | 359.00K | 2.69M | 538.40K |
| EBITDA | -2.33M | -2.28M | -2.81M | -7.36M | -2.19M | -2.24M |
| Net Income | -2.42M | -2.42M | -2.96M | -7.84M | -2.09M | -1.85M |
Balance Sheet | ||||||
| Total Assets | 2.83M | 2.83M | 2.77M | 2.75M | 11.52M | 2.06M |
| Cash, Cash Equivalents and Short-Term Investments | 1.06M | 1.06M | 870.00K | 234.00K | 6.69M | 369.00K |
| Total Debt | 491.00K | 491.00K | 817.00K | 1.08M | 1.31M | 78.00K |
| Total Liabilities | 1.45M | 1.45M | 1.88M | 2.45M | 3.47M | 1.96M |
| Stockholders Equity | 1.38M | 1.38M | 887.00K | 304.00K | 8.05M | 105.00K |
Cash Flow | ||||||
| Free Cash Flow | -1.98M | -2.01M | -2.41M | -6.09M | -2.79M | -1.26M |
| Operating Cash Flow | -1.97M | -2.00M | -2.28M | -4.06M | -2.38M | -1.10M |
| Investing Cash Flow | -92.00K | -92.00K | -122.00K | -2.03M | -418.00K | -339.20K |
| Financing Cash Flow | 2.28M | 2.28M | 3.04M | -365.00K | 9.12M | 1.50M |
Aptamer Group Plc Technical Analysis
Aptamer Group Plc Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
75 Outperform | £96.66M | 12.73 | 64.40% | 8.33% | -3.61% | -6.35% | |
56 Neutral | £30.77M | -3.69 | -204.29% | ― | 3.31% | 21.91% | |
52 Neutral | £23.60M | -6.25 | -213.66% | ― | 39.88% | 81.33% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
44 Neutral | £16.88M | -9.38 | -164.37% | ― | -11.43% | 23.40% | |
42 Neutral | £225.26M | ― | ― | ― | ― | ― | |
38 Underperform | £11.80M | -0.29 | -407.49% | ― | 72.17% | 79.03% |
Aptamer Group Plc Corporate Events
Aptamer Group has reported £190,000 of new fee-for-service contracts and extensions, largely driven by repeat Optimer® development work with top‑tier global pharmaceutical companies, lifting its FY26 fee-for-service order book to more than £2.1 million and reinforcing the growing adoption of its platform. The company also received its first £80,000 in cash licensing receipts from a non-exclusive hot‑start PCR Optimer® licence, a high-margin income stream that is expected, based on customer forecasts, to cover around 15% of annual overhead over the next three years, while additional licensing opportunities in diagnostics, tools and therapeutics, combined with a cash runway to June 2027, bolster revenue visibility and management’s confidence in ongoing growth and progress towards cash-flow break-even.
The most recent analyst rating on (GB:APTA) stock is a Hold with a £0.88 price target. To see the full list of analyst forecasts on Aptamer Group Plc stock, see the GB:APTA Stock Forecast page.
Aptamer Group plc issued a brief trading update to address media comment and speculation following an earlier announcement, reiterating that its current cash resources provide funding headroom through to June 2027. The confirmation of this cash runway aims to reassure investors and other stakeholders about the company’s near- to medium-term financial stability and its ability to continue executing its strategy without immediate need for additional financing.
The most recent analyst rating on (GB:APTA) stock is a Hold with a £1.00 price target. To see the full list of analyst forecasts on Aptamer Group Plc stock, see the GB:APTA Stock Forecast page.
Aptamer Group reported a 27% year-on-year rise in unaudited first-half revenue to £0.83 million, backed by a fee-for-service order book of more than £2.0 million for FY26 and a £3.1 million sales pipeline, giving the board confidence that full-year revenue will materially exceed last year. The Group has accelerated its transition from development to commercialisation, signing non-exclusive licensing deals with Twist Bioscience and Alphazyme that bring immediate payments and future royalties, advancing additional licensing discussions for its Optimer® binders in diagnostics and enzymes, and securing a top-three pharmaceutical partner for radioligand development alongside substantial repeat contracts from other top-tier pharma clients. Progress with Unilever programmes, new Optimer® IHC reagents for a global diagnostics company, and a de-risked fibrotic liver therapeutic candidate collectively strengthen Aptamer’s IP base and validate its dual revenue strategy, positioning the company for higher-margin, recurring income streams and reinforcing its standing as a niche technology partner to blue-chip players across pharma, diagnostics and consumer goods.
The most recent analyst rating on (GB:APTA) stock is a Hold with a £1.00 price target. To see the full list of analyst forecasts on Aptamer Group Plc stock, see the GB:APTA Stock Forecast page.
Aptamer Group has signed a non-exclusive worldwide OEM licensing agreement with Alphazyme, a Maravai LifeSciences company, for an enzyme‑modulating Optimer® used in hot‑start PCR and next-generation sequencing applications. The deal, which follows a successful development programme completed in late 2024, includes royalties on Alphazyme’s product sales, milestone payments, and a supply agreement under which Aptamer will manufacture the Optimer®, creating additional revenue streams and supply-chain leverage. The Optimer® binder enables temperature‑sensitive control of key enzyme activities and can replace two traditional antibodies with a single molecule, offering performance and cost advantages; this second enzyme‑modulation licence with Alphazyme is presented by Aptamer as a commercial and technical validation of its Optimer® platform and is expected to support further licensing opportunities and expansion of both companies’ product portfolios.
The most recent analyst rating on (GB:APTA) stock is a Hold with a £0.77 price target. To see the full list of analyst forecasts on Aptamer Group Plc stock, see the GB:APTA Stock Forecast page.
Aptamer Group plc has entered into a non-exclusive licensing agreement with Twist Bioscience, a leader in synthetic biology and genomics, to commercialize its Optimer® binder technology in the next-generation sequencing (NGS) market. This partnership allows Aptamer to supply its proprietary binders to Twist Bioscience, maximizing the value of its intellectual property and enabling participation in the growing NGS market, projected to reach $23.6 billion by 2029. The agreement supports Aptamer’s strategy of building a licensing-led revenue model, providing sustainable income through upfront payments and royalties, while enhancing its market position alongside a proven industry leader.
The most recent analyst rating on (GB:APTA) stock is a Hold with a £0.50 price target. To see the full list of analyst forecasts on Aptamer Group Plc stock, see the GB:APTA Stock Forecast page.
Aptamer Group PLC has reported significant commercial momentum and strategic progress, highlighted by contract wins with major pharmaceutical companies, resulting in a robust order book for FY26. The company has launched a Biomarker Discovery Service to enhance revenue streams and has raised £1.8 million to support operational expansion. With a focus on licensing deals and intellectual property retention, Aptamer is well-positioned for future growth and shareholder value enhancement.
The most recent analyst rating on (GB:APTA) stock is a Hold with a £0.50 price target. To see the full list of analyst forecasts on Aptamer Group Plc stock, see the GB:APTA Stock Forecast page.
Aptamer Group plc has announced significant contract wins totaling £192,000, contributing to a robust FY26 order book of £1.95 million. These contracts, including a repeat engagement with a top 5 global pharmaceutical company, highlight the company’s growing commercial momentum and the validation of its Optimer® technology. The company’s strategy of securing fee-for-service contracts while building a valuable intellectual property portfolio is proving successful, positioning Aptamer for long-term value through licensing and royalties. With strong demand from top-tier pharmaceutical companies and a replenished sales pipeline, Aptamer is confident in exceeding last year’s revenue and advancing towards therapeutic partnerships.
The most recent analyst rating on (GB:APTA) stock is a Hold with a £0.50 price target. To see the full list of analyst forecasts on Aptamer Group Plc stock, see the GB:APTA Stock Forecast page.
Aptamer Group has secured a significant new contract with a top five pharmaceutical company, valued at up to £617,000, marking the third project with this partner. This contract highlights the commercial validation and increasing traction of Aptamer’s Optimer® technology platform, as it will develop binders against three key drug targets. The company retains full intellectual property rights, opening future licensing revenue opportunities. With a 46% increase in contract value visibility compared to last year, Aptamer is well-positioned for sustained revenue growth, reinforcing its foundation of repeat business with leading pharmaceutical partners.
The most recent analyst rating on (GB:APTA) stock is a Hold with a £0.50 price target. To see the full list of analyst forecasts on Aptamer Group Plc stock, see the GB:APTA Stock Forecast page.
Aptamer Group plc has announced the posting of its Annual Report and Accounts for the year ending 30 June 2025, along with the Notice of its 2025 Annual General Meeting (AGM) to shareholders. The AGM is scheduled for 27 November 2025 and will be held in person, with results of voting to be announced to the London Stock Exchange and published on the company’s website.
The most recent analyst rating on (GB:APTA) stock is a Hold with a £0.50 price target. To see the full list of analyst forecasts on Aptamer Group Plc stock, see the GB:APTA Stock Forecast page.